Susquehanna International Group’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.72M Buy
383,900
+174,000
+83% +$870K ﹤0.01% 6530
2025
Q4
$1.11M Buy
209,900
+16,200
+8% +$81.5K ﹤0.01% 6947
2025
Q3
$1.02M Buy
193,700
+73,700
+61% +$467K ﹤0.01% 7306
2025
Q2
$682K Buy
120,000
+97,300
+429% +$554K ﹤0.01% 8432
2025
Q1
$108K Buy
+22,700
New +$123K ﹤0.01% 11491
2024
Q4
Sell
-27,000
Closed -$171K 12072
2024
Q3
$171K Buy
27,000
+9,400
+53% +$49.1K ﹤0.01% 10617
2024
Q2
$74.6K Buy
17,600
+4,100
+30% +$20.9K ﹤0.01% 11210
2024
Q1
$97.9K Sell
13,500
-22,100
-62% -$140K ﹤0.01% 11231
2023
Q4
$178K Buy
+35,600
New +$157K ﹤0.01% 10798
2021
Q3
Sell
-736
Closed -$29K 12640
2021
Q2
$29K Sell
736
-1,380
-65% -$56.3K ﹤0.01% 12389
2021
Q1
$99K Buy
2,116
+1,648
+352% +$90.8K ﹤0.01% 11865
2020
Q4
$18K Buy
+468
New +$15.9K ﹤0.01% 10890
2020
Q3
Sell
-1,056
Closed -$77K 10466
2020
Q2
$77K Sell
1,056
-752
-42% -$52K ﹤0.01% 9609
2020
Q1
$95K Buy
1,808
+576
+47% +$38.5K ﹤0.01% 9355
2019
Q4
$101K Buy
1,232
+636
+107% +$44.9K ﹤0.01% 9134
2019
Q3
$34K Buy
596
+156
+35% +$11.7K ﹤0.01% 9868
2019
Q2
$53K Sell
440
-452
-51% -$75.8K ﹤0.01% 9827
2019
Q1
$164K Sell
892
-1,484
-62% -$265K ﹤0.01% 7982
2018
Q4
$424K Sell
2,376
-680
-22% -$148K ﹤0.01% 6345
2018
Q3
$978K Sell
3,056
-4,020
-57% -$1.43M ﹤0.01% 5252
2018
Q2
$2.83M Buy
7,076
+1,304
+23% +$570K ﹤0.01% 3467
2018
Q1
$2.07M Sell
5,772
-2,652
-31% -$985K ﹤0.01% 3848
2017
Q4
$3.34M Buy
8,424
+480
+6% +$199K ﹤0.01% 3070
2017
Q3
$3.39M Buy
7,944
+7,352
+1,242% +$1.98M ﹤0.01% 3049
2017
Q2
$95K Sell
592
-220
-27% -$30K ﹤0.01% 8707
2017
Q1
$102K Sell
812
-276
-25% -$35.6K ﹤0.01% 8381
2016
Q4
$132K Buy
+1,088
New +$170K ﹤0.01% 8937

Other funds holding ABEO

Susquehanna International Group's ABEO Position: Q1 2026 in Review

Susquehanna International Group reduced its Abeona Therapeutics (ABEO) stake by 38% in Q1 2026, selling an estimated $1.34M and leaving 432,370 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #6263.

Susquehanna International Group first reported a position in ABEO in Q3 2016 and has held it in 27 quarters since. The position peaked at $3.7M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Susquehanna International Group held 432,370 shares of Abeona Therapeutics worth $1.94M as of Q1 2026.
  • Susquehanna International Group sold 268,918 Abeona Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Abeona Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6263 holding.
  • Susquehanna International Group first reported a position in Abeona Therapeutics in Q3 2016 and has held it in 27 quarters since.
  • Susquehanna International Group's Abeona Therapeutics position peaked at $3.7M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.